SKP2 and cancer: Zhao and co‐workers demonstrated this using SKP2 knockout mice and found that loss of p53 and pRB in these mice blocked tumorigenesis due to cell cycle arrest mediated by accumulated p27, suggesting that SKP2 could be a promising target for p53 mutant cancer therapy.107